What is the recommended management of herpes zoster?

Management of Herpes Zoster (Shingles)

Antiviral Therapy

For acute herpes zoster, initiate oral antiviral therapy within 72 hours of rash onset with one of the following first-line agents: valacyclovir 1g three times daily, famciclovir 500mg three times daily, or acyclovir 800mg five times daily for 7-10 days. 1, 2

Specific Antiviral Regimens

First-line options (choose one):

• Valacyclovir 1g orally three times daily for 7 days 1, 2
• Famciclovir 500mg orally three times daily for 7 days 1, 2
• Acyclovir 800mg orally five times daily for 7 days 1, 2
• Brivudin 125mg orally once daily for 7 days (where available in Europe) 2

Key treatment principles:

• Treatment should ideally begin within 72 hours of rash onset to maximize benefit in reducing acute pain severity, duration of viral shedding, and risk of postherpetic neuralgia (PHN) 1, 2
• Extend treatment beyond 7-10 days if new lesions continue to appear or healing is incomplete 1
• Valacyclovir and famciclovir offer superior bioavailability and more convenient dosing compared to acyclovir 2

Severe Disease or Complications

For patients requiring hospitalization due to severe disease, disseminated infection, or complications (encephalitis, pneumonitis, hepatitis, ophthalmic involvement):

• Acyclovir 10-15 mg/kg IV every 8 hours until clinical improvement, then transition to oral therapy 1, 2

Special Populations

Immunocompromised patients:

• Require more aggressive and prolonged antiviral therapy 1
• Consider IV acyclovir initially, especially for severe presentations 1
• Monitor closely for treatment failure and complications 1

Ophthalmic zoster:

• Requires urgent ophthalmology consultation 1
• Initiate oral antivirals immediately 1

Pain Management

Acute Pain (During Active Infection)

Implement multimodal analgesia based on pain severity:

Mild to moderate pain:

• Acetaminophen or NSAIDs as first-line 3
• Add gabapentin 300-600mg three times daily if inadequate response 3

Moderate to severe pain:

• Gabapentin starting at 300mg daily, titrating to 300-600mg three times daily 3
• Pregabalin 75-150mg twice daily as alternative 3
• Consider adding opioid analgesics (tramadol, oxycodone) for breakthrough pain 3

Early initiation strategy:

• For patients at high risk of developing PHN (age >50, severe acute pain, extensive rash, prodromal pain), start gabapentin or tricyclic antidepressant early during acute phase 3

Postherpetic Neuralgia (PHN)

For established PHN (pain persisting >90 days after rash onset), use the following treatment hierarchy:

First-line systemic agents (in order of preference):

1. Gabapentin 300-3600mg daily in divided doses 3
2. Pregabalin 150-600mg daily in divided doses 3
3. Tricyclic antidepressants: amitriptyline, nortriptyline, or desipramine 25-150mg daily 3

Second-line agents:

• Opioid analgesics (tramadol, morphine, oxycodone, methadone) for refractory cases 3

Topical therapies:

• Lidocaine 5% patches applied to affected area for up to 12 hours daily 3
• Capsaicin 8% patch (single application by healthcare provider) 3
• Capsaicin 0.075% cream applied 3-4 times daily 3

Local/Supportive Care

Topical measures:

• Keep lesions clean and dry 1
• Calamine lotion or cooling compresses for symptomatic relief 1
• Avoid topical acyclovir (substantially less effective than systemic therapy) 4

Vaccination for Prevention

Primary Prevention

All immunocompetent adults aged ≥50 years should receive herpes zoster vaccination, with strong preference for the recombinant zoster vaccine (RZV/Shingrix) over live attenuated vaccine (ZVL/Zostavax). 4, 5

Recombinant Zoster Vaccine (RZV/Shingrix) - Preferred:

• Two-dose series: 0.5mL IM, second dose 2-6 months after first dose 4, 5
• Vaccine efficacy: 97.2% in adults ≥50 years, 91.3% in adults ≥70 years 4
• Protection persists >83% for 8 years, 73% at 10 years 4
• Safe for immunocompromised individuals 5
• Common adverse effects: injection site reactions (9.5%) and systemic symptoms (11.4%) including myalgia, fatigue, headache 4

Live Attenuated Vaccine (ZVL/Zostavax) - Alternative:

• Single dose 0.65mL subcutaneously 4
• Vaccine efficacy: 51-70% depending on age (lower efficacy in older adults) 4
• Efficacy wanes significantly over time 4
• Contraindicated in immunocompromised patients 4

Vaccination after herpes zoster episode:

• Administer RZV regardless of prior zoster history 4
• No minimum interval required between acute zoster and vaccination 4

Infection Control

For hospitalized patients:

• Airborne and contact precautions until lesions are crusted 6
• Immunocompromised patients with disseminated disease require strict isolation 6

Common Pitfalls to Avoid

• Do not delay antiviral therapy waiting for laboratory confirmation; clinical diagnosis is sufficient 1, 2
• Do not use topical acyclovir as monotherapy; it is substantially inferior to oral antivirals 4
• Do not withhold antivirals in patients presenting >72 hours after rash onset if new lesions are still forming or if patient has ophthalmic involvement, is immunocompromised, or has moderate-to-severe pain 1, 2
• Do not assume birth before 1980 confers immunity to varicella in healthcare workers or pregnant women when considering zoster vaccination eligibility 4